Tardive dyskinesia : we are not there yet

Abstract EN

TArdive Dyskinesia is one of the more complex movement disorders for patients and mental health workers.

It is relatively easy to diagnose but rather difficult to treat.

It was not until 2017 when the FDA approved two drugs to treat the disorder.

Many of the dopamine receptor blocking agents DRBA are reported to cause the disorder.

Many mechanisms have been proposed for the appearance of this disorder and many risk factors were reported to facilitate the appearance of the disorder in patients treated with those drugs.

Neither drugs approved by FDA nor other putative treatments that did not gain FDA approval could lead to complete disappearance of the symptoms.

The best approach is a practice the ensures the prevention of the occurrence of the disorder because we are not there yet.